CPT code 38214 denotes preparation of hematopoietic progenitor cells (HPCs) resulting in a product with minimal plasma volume, a step intended to concentrate cells and reduce infusion volume during transplantation. This code is relevant nationally for transplant centers, hospital laboratories, and payers as cellular therapy and hematopoietic stem cell transplantation continue to be central to hematology-oncology care. Typical claim activity involves hospital-based or specialized cellular therapy lab settings where processing occurs prior to infusion.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for the service, where it is typically performed, and what the code represents. The publication outlines reimbursement benchmarks and payer coverage patterns where available, highlights relevant billing and documentation considerations for claims involving cellular product preparation, and summarizes policy developments that affect coverage and payment for HPC processing. Clinical context explains why minimal plasma volume products are used and how the preparation supports transplantation logistics and patient management. Data not available in the input are noted where applicable.